An Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2586881 in Participants With Pulmonary Arterial Hypertension
Latest Information Update: 28 Jun 2023
Price :
$35 *
At a glance
- Drugs Alunacedase alfa (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 17 Jun 2019 Status changed from recruiting to completed.
- 06 Jun 2019 This trial has been completed in Spain, according to European Clinical Trials Datab
- 10 Aug 2018 Planned number of patients changed from 25 to 24.